| Description | Delpazolid (LCB01-0371), also known as LCB01-0371, is a new oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was more active than linezolid against these systemic infections. LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus. |
| Target activity | MSSA:2 μg/mL (MIC90), MRSA:2 μg/mL (MIC90) |
| Synonyms | LCB01-0371 |
| molecular weight | 308.31 |
| Molecular formula | C14H17FN4O3 |
| CAS | 1219707-39-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 13 mg/mL (42.17 mM), Sonication is recommended. |
| References | 1. Jeong JW, et al.In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.Antimicrob Agents Chemother. 2010 Dec;54(12):5359-62. Jeong JW1, 2. Kim TS,et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02752-16.Kim TS1,2, 3. Choi Y,et al.Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects. J Antimicrob Chemother. 2017 Oct 23. doi: 10.1093/jac/dkx367. |